Table 4.
Association of Outcomes With Therapy Type and Timely Reperfusion
| Outcome | Fibrinolytics vs PPCI | DTN ≤30 vs DTN >30 | DTB <90 vs DTB >90 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted OR (95% CI) | P Value | Adjusted OR (95% CI) | P Value | Unadjusted OR (95% CI) | P Value | Adjusted OR (95% CI) | P Value | Unadjusted OR (95% CI) | P Value | Adjusted OR (95% CI) | P Value | |
| In‐hospital mortality | 1.26 (0.94‐1.70) | 0.12 | 1.22 (0.94‐1.58) | 0.14 | 0.59 (0.37‐0.95) | 0.03 | 0.79 (0.47‐1.33) | 0.37 | 0.52 (0.41‐0.66) | <0.0001 | 0.63 (0.49‐0.79) | 0.0001 |
| Length of stay ≥4 days | 1.51 (1.28‐1.77) | <0.0001 | 1.53 (1.29‐1.83) | <0.0001 | 0.76 (0.61‐0.95) | 0.01 | 0.87 (0.68‐1.10) | 0.23 | 0.65 (0.60‐0.70) | <0.0001 | 0.71 (0.65‐0.78) | <0.0001 |
| Aspirin within 24 hours | 0.71 (0.51‐0.98) | 0.04 | 0.69 (0.51‐0.93) | 0.01 | 0.77 (0.54‐1.10) | 0.14 | 0.79 (0.55‐1.14) | 0.21 | 1.42 (1.15‐1.75) | 0.001 | 1.37 (1.06‐1.76) | 0.02 |
| Aspirin at discharge | 0.85 (0.60‐1.21) | 0.37 | 0.92 (0.63‐1.34) | 0.65 | 1.03 (0.61‐1.76) | 0.91 | 1.02 (0.58‐1.79) | 0.96 | 1.26 (0.86‐1.84) | 0.24 | 1.12 (0.74‐1.69) | 0.61 |
| Smoking cessation advice given | 0.87 (0.64‐1.18) | 0.37 | 0.86 (0.62‐1.20) | 0.38 | 1.09 (0.62‐1.91) | 0.76 | 1.09 (0.66‐1.81) | 0.73 | 1.16 (0.91‐1.48) | 0.23 | 1.15 (0.88‐1.51) | 0.30 |
| ACE‐I/ARB for LVSD at discharge | 0.92 (0.60‐1.40) | 0.69 | 0.91 (0.59‐1.40) | 0.66 | 0.75 (0.40‐1.40) | 0.36 | 0.58 (0.25‐1.39) | 0.23 | 2.00 (1.50‐2.65) | <0.0001 | 1.73 (1.26‐2.38) | 0.0008 |
| β‐Blockers at discharge | 0.69 (0.47‐1.00) | 0.05 | 0.75 (0.49‐1.13) | 0.16 | 0.86 (0.53‐1.39) | 0.53 | 0.88 (0.54‐1.42) | 0.60 | 1.41 (1.05‐1.90) | 0.02 | 1.36 (0.97‐1.89) | 0.07 |
| Statins or lipid‐lowering drugs at discharge for patients with LDL‐C >100 mg/dL | 0.81 (0.58‐1.13) | 0.21 | 0.83 (0.59‐1.17) | 0.29 | 1.24 (0.79‐1.93) | 0.36 | 1.21 (0.72‐2.05) | 0.48 | 1.08 (0.79‐1.46) | 0.64 | 1.01 (0.71‐1.42) | 0.98 |
Adjusted for age, sex, race, insurance, body mass index (BMI), height, medical history including anemia, atrial fibrillation, atrial flutter, coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD) or asthma, cardiac resynchronization therapy‐defibrillator (CRT‐D), cardiac resynchronization therapy‐pacemaker (CRT‐P), cerebrovascular accident (CVA)/transient ischemic attack (TIA), diabetes, heart failure, hyperlipidemia, hypertension, implantable cardioverter defibrillator (ICD), pacemaker, peripheral vascular disease (PVD), coronary artery bypass graft (CABG), prior myocardial infarction (MI), prior percutaneous coronary intervention (PCI), renal insufficiency, valvular heart disease, smoking; hospital characteristics (region, hospital type, number of beds, rural vs urban, admission year‐quarter). ACE‐I indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CI, confidence interval; DTB, door to balloon; DTN, door to needle; LDL, low‐density lipoprotein; LVSD, left ventricular systolic dysfunction; OR, odds ratio; PPCI, primary percutaneous coronary intervention.